Rebif® (interferon beta-1a)

Parent company: EMD Serono, Inc. and Pfizer Inc A German study looked at the effects of interferons and Copaxone on pregnancy and relapse rate. This study re-confirmed the reduced MS relapse rate during pregnancy and the increased relapse rate after birth. Exclusive breastfeeding seemed to have beneficial effects on postpartum relapse-rate reduction. While these data also support previous findings that the interferons and Copaxone do not present a major risk for birth defects, anyone who is pregnant or plans on becoming pregnant should discuss the risks and the benefits with her doctor before starting or continuing any disease-modifying therapy.